U
Menu
M
Donate

ARMGO Phase 2 Trial for the Treatment of CPVT

ARMGO Clinical Drug Trial for the Treatment of CPVT

ARMGO recently began enrolling participants for a clinical drug trial for the treatment of CPVT.

The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo Clinic, Rochester MN, USA will investigate the safety and efficacy of the drug ARM210 in CPVT.

FAQs

What is the drug being investigated, and how does it work?

This drug (ARM210) is a potential disease-modifying therapy for CPVT. It repairs leaky RYR2 channels. By binding and stabilizing the leaky channel, ARM210 can restore normal heart function (as demonstrated in animal models). This trial is in Phase 2 and is now recruiting participants with RYR2 CPVT.

What are the basic eligibility criteria?

  1. Participants must be 18 to 65 years of age
  2. Participants must have a genetic diagnosis of an RYR2 mutation. That means they must have been genetically tested.
  3. Female participants can’t be pregnant or breastfeeding

Where are the trial sites and how often would I need to travel there?

Patients will be required to travel to either the Amsterdam University Medical Center in Amsterdam or the Mayo Clinic in Rochester, MN four times during the study to participate.

The information contained herein is being made available as a public service by the SADS Foundation (SADS). No posted information or material provided is intended to constitute medical or professional advice. SADS makes no representations or warranties, either express or implied, as to the accuracy of any posted information and assumes no responsibility for any errors or omissions contained therein. SADS makes no representations or warranties, either express or implied, that any products or services adhere to or satisfy any standards or requirements that may be applicable to such product or service. Furthermore, no warranty, express or implied, is created by providing information and does not in any way constitute an endorsement by SADS. No one shall be entitled to claim detrimental reliance on any views or information, or to claim any duty on the part of SADS to update posted information. In no event shall SADS be held liable to you or anyone else for any decision made or action taken in reliance on such information or views.